M&A: NKGen Biotech, Inc.

Form Type: 8-K

Filing Date: 2025-01-02

Corporate Action: Acquisition

Type: Update

Accession Number: 000121390025000418

Comments: On December 31, 2024, NKGen Biotech, Inc. was notified by the Seoul Bankruptcy Court that it has been selected as the final preferred bidder for acquiring a controlling interest in NKMAX Co. Ltd., a significant shareholder of the Company. NKMAX is a biotechnology firm focused on immune cell therapies, and is currently undergoing rehabilitation efforts, with trading on the KOSDAQ suspended. The Company will deposit the remaining acquisition price into a designated bank account within five business days prior to an upcoming stakeholders' meeting for NKMAX's rehabilitation plan. Additionally, a seventh amendment to a forward purchase agreement with Meteora Strategic Capital, LLC and affiliates was executed to extend the valuation date to December 31, 2025, with all other terms remaining unchanged.

Document Link: View Document